The HDAC inhibitors trichostatin A and suberoylanilide hydroxamic acid exhibit multiple modalities of benefit for the vascular pathobiology of sickle transgenic mice

The vascular pathobiology of sickle cell anemia involves inflammation, coagulation, vascular stasis, reperfusion injury, iron-based oxidative biochemistry, deficient nitric oxide (NO) bioavailability, and red cell sickling. These disparate pathobiologies intersect and overlap, so it is probable that...

Full description

Saved in:

Bibliographic Details
Published in:	Blood Vol. 115; no. 12; pp. 2483 - 2490
Main Authors:	Hebbel, Robert P., Vercellotti, Gregory M., Pace, Betty S., Solovey, Anna N., Kollander, Rahn, Abanonu, Chine F., Nguyen, Julia, Vineyard, Julie V., Belcher, John D., Abdulla, Fuad, Osifuye, Shadé, Eaton, John W., Kelm, Robert J., Slungaard, Arne
Format:	Journal Article
Language:	English
Published:	Washington, DC Elsevier Inc 25-03-2010 Americain Society of Hematology American Society of Hematology
Series:	Red Cells, Iron, and Erythropoiesis
Subjects:	Anemia, Sickle Cell - drug therapy Anemia, Sickle Cell - genetics Anemia, Sickle Cell - metabolism Anemias. Hemoglobinopathies Animals beta-Thalassemia - drug therapy beta-Thalassemia - genetics beta-Thalassemia - metabolism Biological and medical sciences Cells, Cultured Disease Models, Animal Diseases of red blood cells Endothelial Cells - cytology Endothelial Cells - drug effects Endothelial Cells - metabolism Enzyme Inhibitors - pharmacology Fetal Hemoglobin - genetics Hematologic and hematopoietic diseases Hemoglobin A - genetics Hemoglobin, Sickle - genetics Histone Deacetylase Inhibitors - pharmacology Humans Hydroxamic Acids - pharmacology Intercellular Adhesion Molecule-1 - metabolism Iron Chelating Agents - pharmacology Medical sciences Mice Mice, Inbred C57BL Mice, Transgenic Pulmonary Veins - cytology Red Cells, Iron, and Erythropoiesis Regional Blood Flow - drug effects Regional Blood Flow - physiology Thromboplastin - metabolism Vascular Cell Adhesion Molecule-1 - metabolism Venules - cytology Venules - physiology Vorinostat Hemoglobinopathy Animal model Sickle cell anemia Hematology Pathophysiology Rodentia Hydroxamic acid Transgenic animal Hemopathy Genetic disease Vertebrata Histone deacetylase inhibitor Hemolytic anemia Mammalia Mouse Blood vessel Circulatory system
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	The vascular pathobiology of sickle cell anemia involves inflammation, coagulation, vascular stasis, reperfusion injury, iron-based oxidative biochemistry, deficient nitric oxide (NO) bioavailability, and red cell sickling. These disparate pathobiologies intersect and overlap, so it is probable that multimodality therapy will be necessary for this disease. We have, therefore, tested a histone deacetylase (HDAC) inhibitor, trichostatin A (TSA), for efficacy in reducing endothelial activation. We found that pulmonary vascular endothelial VCAM-1 and tissue factor (TF) expression (both are indicators of endothelial activation) are powerfully and significantly inhibited by TSA. This is seen both with pretreatment before the inducing stress of hypoxia/reoxygenation (NY1DD sickle transgenic mouse), and upon longer-term therapy after endothelial activation has already occurred (hBERK1 sickle mouse at ambient air). In addition, TSA prevented vascular stasis in sickle mice, it exhibited activity as an iron chelator, and it induced expression of the antisickling hemoglobin, hemoglobin F. Notably, the TSA analog SAHA (suberoylanilide hydroxaminc acid) that is already approved for human clinical use exhibits the same spectrum of biologic effects as TSA. We suggest that SAHA possibly could provide true, multimodality, salubrious effects for prevention and treatment of the chronic vasculopathy of sickle cell anemia.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	0006-4971 1528-0020
DOI:	10.1182/blood-2009-02-204990